KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 170 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $346,938 | -36.3% | 258,909 | -14.9% | 0.00% | – |
| Q2 2023 | $544,774 | -37.1% | 304,343 | +36.7% | 0.00% | – |
| Q1 2023 | $866,346 | +23.2% | 222,711 | +7.7% | 0.00% | – |
| Q4 2022 | $703,225 | -35.8% | 206,831 | +3.2% | 0.00% | – |
| Q3 2022 | $1,095,000 | +21.4% | 200,501 | +0.3% | 0.00% | – |
| Q2 2022 | $902,000 | -37.0% | 199,977 | +3.0% | 0.00% | – |
| Q1 2022 | $1,432,000 | +18.3% | 194,197 | +3.2% | 0.00% | – |
| Q4 2021 | $1,210,000 | +10.4% | 188,149 | 0.0% | 0.00% | – |
| Q3 2021 | $1,096,000 | -77.2% | 188,149 | -59.5% | 0.00% | -100.0% |
| Q2 2021 | $4,800,000 | +0.9% | 465,058 | +2.8% | 0.00% | 0.0% |
| Q1 2021 | $4,758,000 | -34.2% | 452,244 | -3.2% | 0.00% | -33.3% |
| Q4 2020 | $7,231,000 | -4.0% | 467,069 | -9.5% | 0.00% | 0.0% |
| Q3 2020 | $7,533,000 | -10.4% | 515,909 | +16.3% | 0.00% | -25.0% |
| Q2 2020 | $8,405,000 | +13.3% | 443,721 | +14.9% | 0.00% | 0.0% |
| Q1 2020 | $7,418,000 | +10.4% | 386,138 | +10.2% | 0.00% | 0.0% |
| Q4 2019 | $6,717,000 | +103.0% | 350,365 | +1.9% | 0.00% | +100.0% |
| Q3 2019 | $3,309,000 | +81.5% | 343,961 | +13.0% | 0.00% | +100.0% |
| Q2 2019 | $1,823,000 | +22.8% | 304,258 | +19.8% | 0.00% | 0.0% |
| Q1 2019 | $1,484,000 | -41.1% | 254,031 | -5.5% | 0.00% | -50.0% |
| Q4 2018 | $2,520,000 | -45.6% | 268,847 | -1.2% | 0.00% | -33.3% |
| Q3 2018 | $4,632,000 | +5.9% | 271,988 | +5.7% | 0.00% | 0.0% |
| Q2 2018 | $4,374,000 | +93.7% | 257,410 | +53.0% | 0.00% | +50.0% |
| Q1 2018 | $2,258,000 | +56.5% | 168,188 | +11.9% | 0.00% | +100.0% |
| Q4 2017 | $1,443,000 | -6.4% | 150,289 | +7.1% | 0.00% | 0.0% |
| Q3 2017 | $1,542,000 | +46.7% | 140,360 | +21.0% | 0.00% | 0.0% |
| Q2 2017 | $1,051,000 | -5.4% | 116,036 | +34.1% | 0.00% | 0.0% |
| Q1 2017 | $1,111,000 | +42.8% | 86,514 | +4.5% | 0.00% | 0.0% |
| Q4 2016 | $778,000 | +26.1% | 82,752 | +30.6% | 0.00% | 0.0% |
| Q3 2016 | $617,000 | +52.0% | 63,364 | +4.7% | 0.00% | 0.0% |
| Q2 2016 | $406,000 | -23.7% | 60,498 | +1.5% | 0.00% | 0.0% |
| Q1 2016 | $532,000 | -31.4% | 59,616 | +1.8% | 0.00% | 0.0% |
| Q4 2015 | $776,000 | +28.7% | 58,545 | +2.4% | 0.00% | 0.0% |
| Q3 2015 | $603,000 | -63.6% | 57,180 | -6.1% | 0.00% | -50.0% |
| Q2 2015 | $1,657,000 | +10.1% | 60,868 | +23.9% | 0.00% | 0.0% |
| Q1 2015 | $1,505,000 | +29.7% | 49,145 | +58.6% | 0.00% | 0.0% |
| Q4 2014 | $1,160,000 | +8.2% | 30,980 | +1.1% | 0.00% | 0.0% |
| Q3 2014 | $1,072,000 | -3.9% | 30,657 | +27.9% | 0.00% | 0.0% |
| Q2 2014 | $1,116,000 | +110.2% | 23,973 | +39.5% | 0.00% | +100.0% |
| Q1 2014 | $531,000 | +37.9% | 17,185 | +2.5% | 0.00% | 0.0% |
| Q4 2013 | $385,000 | – | 16,765 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $35,031,000 | 23.03% |
| Palo Alto Investors LP | 5,267,652 | $81,543,000 | 4.28% |
| Fairmount Funds Management LLC | 702,351 | $10,872,000 | 3.89% |
| Birchview Capital, LP | 188,000 | $2,910,000 | 1.68% |
| Mesirow Financial Investment Management, Inc. | 22,303 | $345,250,000 | 1.09% |
| EMERALD ADVISERS, LLC | 1,822,781 | $28,217,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,661,236 | $25,716,000 | 0.90% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,552,504 | $24,033,000 | 0.85% |
| Altium Capital Management LP | 133,951 | $2,074,000 | 0.77% |
| Hood River Capital Management LLC | 931,754 | $14,424,000 | 0.48% |